He D - Search Results

1

Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.

Gu C, Wang Z, Lin T, Liu Z, Han W, Zhang X, Liang C, Liu H, Yu Y, Xu Z, Liu S, Wang J, Jia L, Yao X, Liao W, Fu C, Tan Z, He G, Zhu G, Fan R, Yang W, Chen X, Liu Z, Zhong L, Shi B, Ding D, Chen S, Wei J, Yao X, Chen M, Lu Z, Xie Q, Hu Z, Wang Y, Guo H, Fan T, Liang Z, Chen P, Wang W, Xu T, Li C, Xing J, Liao H, He D, Wu Z, Yu J, Feng Z, Yang M, Dou Q, Zeng Q, Li Y, Gou X, Zhou G, Wang X, Zhu R, Zhang Z, Zhang B, Tan W, Qu X, Sun H, Gan T, Ye D. Gu C, et al. Among authors: he d, he g. Chin Med J (Engl). 2023 May 20;136(10):1207-1215. doi: 10.1097/CM9.0000000000002638. Epub 2023 Apr 3. Chin Med J (Engl). 2023. PMID: 37010251 Free PMC article. Clinical Trial.

2

Astragalus membranaceus reduces free radical-mediated injury to renal tubules in rabbits receiving high-energy shock waves.

Sheng BW, Chen XF, Zhao J, He DL, Nan XY. Sheng BW, et al. Chin Med J (Engl). 2005 Jan 5;118(1):43-9. Chin Med J (Engl). 2005. PMID: 15642225

3

Comparison of seven screening methods in the diagnosis of bladder cancer.

Sun Y, He DL, Ma Q, Wan XY, Zhu GD, Li L, Luo Y, He H, Yang L. Sun Y, et al. Chin Med J (Engl). 2006 Nov 5;119(21):1763-71. Chin Med J (Engl). 2006. PMID: 17097029

4

Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms.

Liu M, Wang J, Yang Y, An R, Wen J, Guan Z, Zheng S, Wang D, Song B, Liao L, Guo H, Xiao J, Sun Y, Shen Z, Kong C, He D, Huang Y, Wang X, Zhang X, Li H, Huang J, Zhao X, Zeng P, Song X, Ye Z. Liu M, et al. Among authors: he d. Chin Med J (Engl). 2014;127(2):261-5. Chin Med J (Engl). 2014. PMID: 24438613

5

A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study.

Ye Z, Hu J, Song X, Li F, Zhao X, Chen S, Wang X, He D, Fan J, Ye D, Xing J, Pan T, Wang D. Ye Z, et al. Among authors: he d. Sci Rep. 2015 Jun 5;5:10905. doi: 10.1038/srep10905. Sci Rep. 2015. PMID: 26046790 Free PMC article. Clinical Trial.

6

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.

Chen R, Huang Y, Cai X, Xie L, He D, Zhou L, Xu C, Gao X, Ren S, Wang F, Ma L, Wei Q, Yin C, Tian Y, Sun Z, Fu Q, Ding Q, Zheng J, Ye Z, Ye D, Xu D, Hou J, Xu K, Yuan J, Gao X, Liu C, Pan T, Sun Y; Chinese Prostate Cancer Consortium. Chen R, et al. Among authors: he d. PLoS One. 2015 Jun 19;10(6):e0130308. doi: 10.1371/journal.pone.0130308. eCollection 2015. PLoS One. 2015. PMID: 26091007 Free PMC article.

7

Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy: A multicenter retrospective study.

Wei D, Wu G, Zheng Y, Chen F, Lu J, Wang Y, He D, Wang H, Wang Z, Chen P, Wang Y, Wang Z, Ye Y, Zhu Z, Yuan J. Wei D, et al. Among authors: he d. Medicine (Baltimore). 2019 Feb;98(5):e14237. doi: 10.1097/MD.0000000000014237. Medicine (Baltimore). 2019. PMID: 30702581 Free PMC article.

8

A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.

He D, Sun Z, Guo J, Zhang Z, Shan Y, Ma L, Li H, Jin J, Huang Y, Xiao J, Wei Q, Ye D. He D, et al. Asia Pac J Clin Oncol. 2019 Jun;15(3):144-150. doi: 10.1111/ajco.13142. Epub 2019 Mar 15. Asia Pac J Clin Oncol. 2019. PMID: 30873737 Free PMC article.

9

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.

Pei X, Wu K, Sun Y, Gao X, Gou X, Xu J, Gao F, He D, Li L; Chinese Prostate Cancer Consortium. Pei X, et al. Among authors: he d. Urol Oncol. 2020 Jan;38(1):2.e11-2.e17. doi: 10.1016/j.urolonc.2019.07.014. Epub 2019 Oct 28. Urol Oncol. 2020. PMID: 31672485

10

Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.

Chung BH, Huang J, Ye ZQ, He DL, Uemura H, Arai G, Kim CS, Zhang YY, Koroki Y, Jeong S, Mundle S, Triantos S, McCarthy S, Chi KN, Ye DW. Chung BH, et al. Asian J Androl. 2022 Mar-Apr;24(2):161-166. doi: 10.4103/aja.aja_64_21. Asian J Androl. 2022. PMID: 34259202 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,386 results

Search Page